| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Since 1998, eEye Digital Security has made vulnerability management simpler, less expensive and more effective by providing the only unified vulnerability and compliance management solution that integrates assessment, mitigation and protection into a complete offering. With a proven history of innovation, eEye has consistently been the first to uncover critical vulnerabilities and prevent their exploit
VenueNext is a technology company on a mission to transform the way people around the world experience venues. VenueNext’s platform unifies the venue infrastructure ecosystem, giving venue owners access to an entirely new suite of sophisticated softwar...
TCM Security is a veteran-owned cybersecurity company that provides penetration testing, security training, and compliance services to businesses of all sizes.
Kansas Internet Services is a Junction City, KS-based company in the Software and Internet sector.